Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

Phase 2 Recruiting 170 enrolled Iovance Biotherapeutics, Inc.

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung cancer

Timeline

Start: 2021-05-07
Primary completion: 2030-12
Completion: 2031-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tumor Infiltrating Lymphocytes	Cell therapy	—	—

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

Summary

Timeline

Drugs

Indications